Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.

Yang L, Dutta SM, Troyer DA, Lin JB, Lance RA, Nyalwidhe JO, Drake RR, Semmes OJ.

Oncotarget. 2015 Dec 22;6(41):43743-58. doi: 10.18632/oncotarget.6193.

2.

CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.

Leroy C, Shen Q, Strande V, Meyer R, McLaughlin ME, Lezan E, Bentires-Alj M, Voshol H, Bonenfant D, Alex Gaither L.

Oncogene. 2015 Oct 29;34(44):5593-8. doi: 10.1038/onc.2015.19.

3.

CUB domain containing protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells.

Orchard-Webb DJ, Lee TC, Cook GP, Blair GE.

BMC Cancer. 2014 Oct 9;14:754. doi: 10.1186/1471-2407-14-754.

4.

Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.

Kollmorgen G, Bossenmaier B, Niederfellner G, Häring HU, Lammers R.

PLoS One. 2012;7(12):e53050. doi: 10.1371/journal.pone.0053050.

5.

Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells.

Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM.

Cancer Res. 2013 Feb 1;73(3):1168-79. doi: 10.1158/0008-5472.CAN-12-2496.

6.

In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI.

Oncogene. 2014 Jan 9;33(2):255-68. doi: 10.1038/onc.2012.547.

7.

CD318/CUB-domain-containing protein 1 expression on cord blood hematopoietic progenitors.

Takeda H, Fujimori Y, Kai S, Ogawa H, Nakano T.

Exp Ther Med. 2010 May;1(3):497-501.

8.

Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.

Law ME, Corsino PE, Jahn SC, Davis BJ, Chen S, Patel B, Pham K, Lu J, Sheppard B, Nørgaard P, Hong J, Higgins P, Kim JS, Luesch H, Law BK.

Oncogene. 2013 Mar 7;32(10):1316-29. doi: 10.1038/onc.2012.138.

9.

Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.

Wortmann A, He Y, Christensen ME, Linn M, Lumley JW, Pollock PM, Waterhouse NJ, Hooper JD.

J Biol Chem. 2011 Dec 9;286(49):42303-15. doi: 10.1074/jbc.M111.227462.

10.

A tumor-suppressing function in the epithelial adhesion protein Trask.

Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM.

Oncogene. 2012 Jan 26;31(4):419-31. doi: 10.1038/onc.2011.246.

11.

The structural features of Trask that mediate its anti-adhesive functions.

Spassov DS, Ahuja D, Wong CH, Moasser MM.

PLoS One. 2011 Apr 29;6(4):e19154. doi: 10.1371/journal.pone.0019154.

12.
13.

P2X(7) receptor antagonists display agonist-like effects on cell signaling proteins.

Hedden L, Benes CH, Soltoff SP.

Biochim Biophys Acta. 2011 May;1810(5):532-42. doi: 10.1016/j.bbagen.2011.03.009.

14.

Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling.

Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM.

Mol Cell Biol. 2011 Feb;31(4):766-82. doi: 10.1128/MCB.00841-10.

15.

Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.

Arcaroli JJ, Touban BM, Tan AC, Varella-Garcia M, Powell RW, Eckhardt SG, Elvin P, Gao D, Messersmith WA.

Clin Cancer Res. 2010 Aug 15;16(16):4165-77. doi: 10.1158/1078-0432.CCR-10-0066.

16.

Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.

He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, Quigley JP, Leduc R, Kirchhofer D, Hooper JD.

J Biol Chem. 2010 Aug 20;285(34):26162-73. doi: 10.1074/jbc.M109.096453.

17.

Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.

Fukuchi K, Steiniger SC, Deryugina E, Liu Y, Lowery CA, Gloeckner C, Zhou B, Kaufmann GF, Quigley JP, Janda KD.

Mol Pharm. 2010 Feb 1;7(1):245-53. doi: 10.1021/mp900236t.

Items per page

Supplemental Content

Support Center